Most clinically relevant T-cell receptor (TCR)-engineered T cells are typically tested in immunocompromised mice, allowing human T-cell engraftment but failing to replicate the complex interactions of a functioning immune system in patients. While humanized mouse models exist, they face challenges with incomplete immune reconstitution and technical complexity.
Researchers from University of Athens and National Centre For Scientific Research “Demokritos” have reported preclinical data from a study that aimed to assess the novel cryptochrome-2 (CRY2) stabilizer TH-301 in models of pancreatic ductal adenocarcinoma (PDAC). It was seen that treatment with TH-301 led to significant dose-, time- and cell type-dependent decreases in viability.
Oxford Drug Design Ltd. has announced additional in vivo validation for its novel approach against cancer. The innovative approach, using generative AI capabilities, is based on the novel target leucyl-tRNA synthetase.
Axcynsis Therapeutics Pte Ltd. has gained IND clearance from the FDA for AT03-65 for the treatment of patients with CLDN6-positive solid tumors. Axcynsis is planning to initiate a phase I trial in the U.S. during the current quarter in patients with advanced CLDN6-positive solid tumors.
Southern Medical University scientists have reported the discovery and preclinical characterization of novel microtubule-inhibiting agents being developed for the treatment of cancer.
Silexion Therapeutics Corp. has released new preclinical results demonstrating the synergistic efficacy of its proprietary second-generation siRNA candidate, SIL-204, in combination with components of first-line chemotherapy for pancreatic cancer.
Can the market justify the hundreds of GLP-1 developers that are working to eventually reach the market? When the dust settles, Minji Kim, CEO of Cross Border Partners and Advisory Service, told attendees at the Biotech Showcase in San Francisco, only a few leading companies will end up dominating the field.
With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies Inc. anticipates a regulatory filing this year seeking accelerated approval from the U.S. FDA, putting the firm on track to receive a potentially profitable rare pediatric disease priority review voucher that could help fund further R&D work. Should OST-HER2 go on to win approval, it would mark the first new therapy in more than 40 years for osteosarcoma, an aggressive bone cancer characterized by high rates of metastases, often to the lungs, and disease recurrence.
Natera Inc., a developer of cell-free DNA testing, provided an update on its product portfolio at the J.P. Morgan Healthcare Conference on Jan. 15. The company disclosed a new version of the Signatera assay that leverages the genome. Natera said the test, now available for research and clinical use, enables bespoke assay design from a whole genome sequence of a patient’s tumor.
RSS
